加载中
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
常规交易时段
US$2.26
−US$0.05 · -2.16%
盘中时间采用ET。市场数据可能有所延迟。
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
日内区间
当前US$2.26
52周区间
当前US$2.26
盘中时间采用ET。市场数据可能有所延迟。
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
日内区间
当前US$2.26
52周区间
当前US$2.26
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 767.9万 USD | 370.5万 USD | 115.9万 USD | — | — |
| 销货成本 | 742.7万 USD | 536.8万 USD | 246.6万 USD | 55.5万 USD | — |
| 毛利 | 25.2万 USD | −166.3万 USD | −130.7万 USD | −55.5万 USD | — |
| 研究与开发 | 1024.1万 USD | 1685.7万 USD | 2436.3万 USD | 1681万 USD | 1180.2万 USD |
| 销售、一般及管理费用 | 1905.5万 USD | 2601.7万 USD | 3733.7万 USD | 3469.4万 USD | 1890.8万 USD |
| 营业费用 | 2929.6万 USD | 4287.4万 USD | 6169.9万 USD | 5150.4万 USD | 4071万 USD |
| 利息支出 | — | 301.9万 USD | 291.2万 USD | 3万 USD | 77.5万 USD |
| 折旧和摊销 | 364.9万 USD | 357.1万 USD | 235.2万 USD | 117万 USD | 58.8万 USD |
| 营业利润 | −2904.4万 USD | −4453.7万 USD | −6300.6万 USD | −5205.9万 USD | −4071万 USD |
| 净利润 | −3324.9万 USD | −4662.5万 USD | −6024.2万 USD | −5581.6万 USD | −4317.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$10.00
上涨空间 342.48%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年7月13日 | 1:20 | — | — |
股票拆分 | 2025年7月14日 | 1:20 | — | — |
股票拆分 | 2017年7月11日 | 1:100 | — | — |
已生效 2026年7月13日
1:20
已生效 2025年7月14日
1:20
已生效 2017年7月11日
1:100
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
